—
Source: Fox News
Summary
Early trials of the experimental injection CBL-514 showed potential for reducing visceral fat, according to research by Dr. W. Timothy Garvey and Yu-Fang Ling. Visceral fat, which surrounds internal organs, is linked to metabolic issues and heart failure risk. A study by the American Heart Association found visceral fat more strongly associated with heart failure than BMI. Phase 2 trials showed CBL-514 reduced subcutaneous fat, and MRI scans indicated a 12.01% decrease in visceral fat in treated participants compared to a 5.68% increase in the placebo group. The injection triggers apoptosis in fat cells without harming surrounding tissue.
Our Reading
This guidance has been heard before.
Visceral fat is a recurring concern in health reporting.
New drugs promise to target it, but the same issues persist.
Studies shift focus from BMI to waistline measurements.
The idea that fat is not just a cosmetic issue is familiar, but still unsettling.
Author: Evan Null
Early Trials of CBL-514
Early human trials of CBL-514, an experimental injection, have shown potential for reducing visceral fat. The trials were conducted by Dr. W. Timothy Garvey of the University of Alabama at Birmingham and Yu-Fang Ling of Caliway Biopharmaceuticals in New Taipei City, Taiwan.
Visceral Fat and Health Risks
Visceral fat, which surrounds internal organs, is linked to metabolic issues, insulin resistance, and type 2 diabetes. A study by the American Heart Association found that visceral fat had a stronger association with heart failure risk than body mass index (BMI).
Phase 2 Trials and Results
Previous phase 2 trials showed that CBL-514 could reduce subcutaneous fat. MRI scans from two phase 2 trials indicated a 12.01% decrease in visceral fat in participants who received the drug, compared to a 5.68% increase in the placebo group.
How CBL-514 Works
The injection selectively triggers apoptosis, a process that causes fat cells to self-destruct, without harming nearby cells. Participants received injections every three weeks for up to 12 weeks, with doses up to 600 milligrams.
Health Impacts and Future Research
Garvey noted that the injection could lead to weight loss, improved blood pressure, and cholesterol, as well as reduced visceral fat. However, the drug is still in early trials, and more research is needed to confirm its long-term effects and safety.
